Amgen’s Q1 2024 Earnings: Revenue Rises, but GAAP EPS Takes a Detour as Horizon Integration Stirs the Plot

Executive snapshot: numbers that rhyme with reality

Amgen (AMGN) reported first-quarter 2024 results that read like a mixed‑signal dashboard: total revenues rose 22% to $7.4 billion, with product sales also up 22% on roughly 25% volume growth. U.S. demand carried more than its share of the weight, with volume up 29% and ex-U.S. volume up 17%. Ten products delivered double-digit volume growth, led by portfolio strength in Repatha (evolocumab), TEZSPIRE, EVENITY, and a slate of oncology and autoimmune medicines.

The Horizon Therapeutics acquisition added a new layer to the story, contributing about $914 million in sales and bringing early-in-life-cycle medicines such as TEPEZZA, KRYSTEXXA, and UPLIZNA into Amgen’s topline. The combo of Horizon’s assets and Amgen’s own growth engines produced a robust top line, even as the company’s GAAP earnings per share took a different path.

On the bottom line, GAAP loss per share was $0.21 for Q1 2024, compared with GAAP earnings per share of $5.28 in Q1 2023. The swing was driven by a mark-to-market loss on Amgen’s BeiGene equity stake and higher operating expenses, including higher amortization from Horizon-acquired assets and incremental Horizon-related costs. In short, the revenue engine was loud; the net income line carried more noise from one-time or non-operating items.

Key drivers: growth, products, and one-time items

• U.S. volume growth of 29% highlights strong domestic demand for Amgen’s portfolio.
• Ex-U.S. volume growth of 17% points to international momentum, though currency and market mix remain a factor for future quarters.
• Ten products delivering double-digit volume growth signals resilience across multiple franchises, including Repatha, TEZSPIRE, EVENITY, BLINCYTO, and TAVNEOS.
• Horizon acquisition added $914 million in sales, underscoring the portfolio diversification and potential mix benefits from the integration of TEPEZZA, KRYSTEXXA, and UPLIZNA.
• GAAP EPS under pressure due to one-time items and higher amortization; the core operating momentum may be obscured by accounting charges rather than fundamental profitability.

Analytical take: what this portends for Amgen and sector peers

From a finance writer’s perch, the headline is straightforward: Amgen logged solid revenue growth supported by a diversified product lineup and a material addition from Horizon. The EPS narrative, however, reminds us that GAAP numbers can swing on one-off items even when the business is doing well. The contrast between a booming top line and a negative GAAP EPS underscores the ongoing tension in big pharma between growth investments, acquisition integration costs, and the accounting treatment of intangible assets and equity investments.

Analysts will be weighing whether the Horizon synergies justify the near-term dilution in GAAP earnings, and whether non-GAAP or management-adjusted metrics better reflect the underlying trajectory. The absence of a visible revenue forecast in the excerpt invites caution; investors will be looking for guidance on margin trajectories, cost containment from the integration, and any revisited cadence for Horizon-related amortization as it migrates from “acquisition capture” to “operating synergy.”

Beyond Amgen, peers in the large-cap biotech/pharma space may take two takeaways. First, acquisitions continue to be a pathway to broaden portfolios, but the market is clearly sensitive to the earnings cadence implied by higher amortization and integration costs. Second, portfolio diversification—where a strong core franchise sits alongside newer or acquired assets—remains a practical hedge against product-cycle risk. In that sense, horizon‑driven dynamics could become a template for peers thinking about how to pace growth and profitability in tandem.

Implications for investors and strategic outlook

For investors focused on EPS and the trajectory of earnings surprise, Amgen’s quarter is a reminder that revenue growth and earnings quality don’t always move in lockstep. The EPS narrative will hinge on how much of the Horizon-related cost base winds down as the integration progresses, how well the branded portfolio sustains its momentum, and whether the BeiGene position stabilizes or requires further re-pricing in risk assets terms.

Strategically, Amgen’s mix- shift through Horizon may push sector peers to accelerate their own product launches or tuck-in acquisitions, but with a caveat: the market seems to reward topline resilience with attention to the cost and timing of integration. In a period when U.S. volume leadership matters, Amgen’s domestic strength may serve as a model for portfolio optimization—emphasizing high-growth franchises while balancing the cash flow impact of acquisitions.

Bottom line and takeaways

Amgen’s first quarter reinforces the core truth of large-cap pharma: revenue growth can outpace earnings numerically when the cost of expansion—both in product development cadence and deal-related amortization—filters into the P&L. The earnings surprise narrative likely leans on non-GAAP adjustments unless GAAP items settle. For now, the stock narrative will hinge on progress in Horizon’s integration, the durability of the core product cycle, and the company’s ability to translate top-line momentum into sustainable profitability. If the sector keeps pace with Amgen’s growth, expect peers to highlight their own pipeline milestones and integration plans as a gauge for the next cycle of earnings reporting.

Bottom line: AMGN’s horizon is bright, but the earnings horizon—measured in EPS consensus and earnings per share realized after one-time effects—still requires patience. The next quarterly update will be the proof point: will the revenue forecast become a path to improved margins, or will the one-time headwinds recede and leave a cleaner earnings story?